You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Dermatology

What We Know About Bullous Pemphigoid (BP): Challenges of the Various Clinical Manifestations, Diagnosis, and Burden for Patients and Caregivers

In this ADVENT symposium at the 2024 EADV meeting, Professor Joost Meijer highlights the heterogeneous nature of BP and the resultant burden for patients.
University Medical Center Groningen Groningen The Netherlands
MD, PhD
Joost Meijer

Learning objectives

  • Describe the heterogenous clinical presentations, disease burden, and diagnosis of bullous pemphigoid (BP)​

Description

Join Professor Joost Meijer as he explores the heterogenous clinical presentations of bullous pemphigoid (BP), addresses the symptoms, disease burden and diagnosis of BP.

Tags
caregiver burdendisease backgroundtype 2 inflammation
MAT-GLB-2406783 - 1.0 - 10/2024

About this expert

Dermatology

Joost Meijer

MD, PhD

Faculty of Medical Sciences Center of Expertise for Blistering Diseases Department of Dermatology University Medical Center Groningen Groningen, The Netherlands

See author’s profile
University Medical Center Groningen Groningen The Netherlands

Related resources

The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions
Dermatology
Infographic

The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management
Dermatology
Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

Expert Case Series: What is the Role of Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?
Dermatology
interactivity

Expert Case Series: What is the Role of Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?

Tools for Clinical Assessment of Prurigo Nodularis
Dermatology
Infographic

Tools for Clinical Assessment of Prurigo Nodularis

AD and PN: Commonalities and Differences – A Case Study
Dermatology
expert video

AD and PN: Commonalities and Differences – A Case Study

Atopic Dermatitis (AD) in Children: Early Intervention Can Reduce Long-Term Disease Impact
Dermatology
expert video

Atopic Dermatitis (AD) in Children: Early Intervention Can Reduce Long-Term Disease Impact

Can Emerging Treatments Help Address Individual PN Patient Burden?
Dermatology
expert video

Can Emerging Treatments Help Address Individual PN Patient Burden?

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children
Dermatology
expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children
Dermatology
expert video

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview
Dermatology
expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview

Differences in Manifestations of Type 2 Inflammatory Diseases
Dermatology
expert video

Differences in Manifestations of Type 2 Inflammatory Diseases

Emerging Clinical Data in Children With Atopic Dermatitis
Dermatology
expert video

Emerging Clinical Data in Children With Atopic Dermatitis

Emerging Clinical Data in Children With Atopic Dermatitis- Q&As
Dermatology
expert video

Emerging Clinical Data in Children With Atopic Dermatitis- Q&As

Emerging Therapeutic Landscape and Implications for Patient Management in CSU
Dermatology
expert video

Emerging Therapeutic Landscape and Implications for Patient Management in CSU

Exploring Prurigo Nodularis: From Definition to Pathology and Patient Management
Dermatology
expert video

Exploring Prurigo Nodularis: From Definition to Pathology and Patient Management

EAACI 2023 | What is New in the Treatment of Children
Dermatology
expert video

EAACI 2023 | What is New in the Treatment of Children

Early Intervention in AD: Latest Clinical and Real-world Data
Dermatology
expert video

Early Intervention in AD: Latest Clinical and Real-world Data

Early Intervention in Children with Atopic Dermatitis: A Window of Opportunity?
Dermatology
expert video

Early Intervention in Children with Atopic Dermatitis: A Window of Opportunity?

Mast Cells and the Neuroimmune Axis in CSU
Dermatology
expert video

Mast Cells and the Neuroimmune Axis in CSU

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children
Dermatology
expert video

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children - Expert Interview
Dermatology
expert video

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children - Expert Interview

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions
Dermatology
expert video

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions

Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis - Expert Interview
Dermatology
expert video

Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis - Expert Interview

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As
Dermatology
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As

Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention? - Q&As
Dermatology
expert video

Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention? - Q&As

Targeting Type 2 Inflammation in Children with AD​
Dermatology
expert video

Targeting Type 2 Inflammation in Children with AD​

IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)
Dermatology
expert video

IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD
Dermatology
expert video

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD

Importance of Barrier Dysfunction in Driving AD Pathophysiology
Dermatology
expert video

Importance of Barrier Dysfunction in Driving AD Pathophysiology

How Should We Define and Classify Prurigo Nodularis?
Dermatology
expert video

How Should We Define and Classify Prurigo Nodularis?

Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis
Dermatology
expert video

Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis

Role of Type 2 Inflammation in Chronic Inflammatory Diseases
Dermatology
expert video

Role of Type 2 Inflammation in Chronic Inflammatory Diseases

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis
Dermatology
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis

Targeted Therapies for Children With Atopic Dermatitis - Expert Interview
Dermatology
expert video

Targeted Therapies for Children With Atopic Dermatitis - Expert Interview

Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention?
Dermatology
expert video

Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention?

Targeting Type 2 Inflammation: ​Skin Barrier Normalization​
Dermatology
expert video

Targeting Type 2 Inflammation: ​Skin Barrier Normalization​

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 
Dermatology
expert video

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview
Dermatology
expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview

Type 2 Inflammation Modulates the Neuroimmune Axis in PN
Dermatology
expert video

Type 2 Inflammation Modulates the Neuroimmune Axis in PN

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis
Dermatology
expert video

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology
Dermatology
expert video

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology

Type 2 Inflammation Alters the Structure and Function of the Skin in AD
Dermatology
expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in AD

Atopic Dermatitis and Prurigo Nodularis: Distinct skin diseases with shared characteristics
Dermatology
Infographic

Atopic Dermatitis and Prurigo Nodularis: Distinct skin diseases with shared characteristics

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis
Dermatology
videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

Exploring Neurosensitization and Pain in Prurigo Nodularis
Dermatology
expert video

Exploring Neurosensitization and Pain in Prurigo Nodularis

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis
Dermatology
videoanimation

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis

Describing Disease Control in PN
Dermatology
expert video

Describing Disease Control in PN

What is Early Intervention in AD?
Dermatology
expert video

What is Early Intervention in AD?

Disease Modification in AD
Dermatology
expert video

Disease Modification in AD

Systemic Inflammation in AD – Beyond the Skin
Dermatology
expert video

Systemic Inflammation in AD – Beyond the Skin

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BrazilChange country/region